Home
Finance
Bank Routing Numbers
FedWire
Stock Portfolio Generator
Technical Analysis of Stocks
Best Months to Buy or Sell Stocks
Games
Hangman - Hang 'Em High
Chess
Shuttles Game
Chemistry
Chemical Equation Balancer
Periodic Table of the Elements
Chemical Bond Polarity Calculator
Linear Algebra
Gauss-Jordan Elimination Calculator
Calculate Pivots
Factorize: A=LU
Inverse Matrix Calculator
Null Space Calculator
Column Space Calculator
Row Space Calculator
Multiply Two Matrices
AI
Genetic Algorithms
Genetic Algorithms Stock Portfolio Generator
Shuttles Game
Tic-Tac-Toe Game
Personality Profile
Checkers Game
Scripts
Scan for all machines running IIS in a domain
Extract data from a Microsoft Word document
Outlook Scripts
Excel Scripts
IT
How to Stop a DDOS Attack
Subnet Calculator
Fingerprint Web Server
Whois Lookup
InternetPeriscope
About
My Favorite Links
Resume
View My Profile on LinkedIn
View My Profile on DataCamp
View My Profile on Pluralsight
Back to FDA Applications sponsored by NOVARTIS
FDA Drug Application 020823 by NOVARTIS
Application Number
020823
Application Type
New Drug Application
Sponsor Applicant
NOVARTIS
Most Recent Label Available Flag
Current Patent Flag
Action Type
Approval
Chemical Type
New molecular entity (NME)
Therapeutic Potential
Standard
Orphan Code
Action Type
Duplicate Counter
Action Date
Document Type
Application Document ID
Sequence Number
Document Title
Document URL
Document Date
AP
0
4/21/2000
N
320
000
http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20823lbl.pdf
4/21/2000
AP
0
4/21/2000
N
1832
000
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20823ltr.pdf
4/21/2000
AP
0
4/21/2000
N
1833
000
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20823_Exelon.cfm
4/21/2000
AP
0
7/11/2000
SCM
AP
0
1/31/2001
SCM
AP
0
1/5/2001
SLR
5620
003
http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20823S3LBL.PDF
1/5/2001
AP
0
1/5/2001
SLR
16795
003
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020823_S003_EXELON_AP.pdf
6/18/2007
AP
0
1/28/2002
SCM
AP
0
1/25/2002
SCM
AP
0
10/16/2002
SCM
AP
0
10/24/2002
SCP
AP
0
10/1/2013
SLR
37323
009
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020823Orig1s009,s027,s028,s029,021025Orig1s018,s019,s0020ltr.pdf
10/4/2013
AP
0
10/1/2013
SLR
37394
009
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020823s009s027s028s029,021025s018s019s020lbl.pdf
10/8/2013
AP
0
5/5/2004
SLR
8545
012
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20823slr012,21025slr006ltr.pdf
5/7/2004
AP
0
9/21/2004
SLR
10273
014
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20823s014,21025s007ltr.pdf
9/24/2004
AP
0
6/27/2006
SE1
14382
016
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf
6/28/2006
AP
0
6/27/2006
SE1
14408
016
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/020823s016, 021025s008ltr.pdf
7/3/2006
AP
0
6/27/2006
SE1
27031
016
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020823_016_exelon.pdf
6/27/2006
AP
0
10/1/2013
SLR
37324
027
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020823Orig1s009,s027,s028,s029,021025Orig1s018,s019,s0020ltr.pdf
10/4/2013
AP
0
10/1/2013
SLR
37395
027
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020823s009s027s028s029,021025s018s019s020lbl.pdf
10/8/2013
AP
0
10/1/2013
SLR
37325
028
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020823Orig1s009,s027,s028,s029,021025Orig1s018,s019,s0020ltr.pdf
10/4/2013
AP
0
10/1/2013
SLR
37393
028
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020823s009s027s028s029,021025s018s019s020lbl.pdf
10/8/2013
AP
0
10/1/2013
SLR
37326
029
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020823Orig1s009,s027,s028,s029,021025Orig1s018,s019,s0020ltr.pdf
10/4/2013
AP
0
10/1/2013
SLR
37396
029
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020823s009s027s028s029,021025s018s019s020lbl.pdf
10/8/2013
AP
0
3/21/2013
SCM
AP
0
4/9/2014
SCM
AP
0
2/3/2015
SLR
41792
032
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020823s032,021025s022lbl.pdf
2/5/2015
AP
0
11/13/2015
SCM
AP
0
1/22/2016
SCM
Back to FDA Applications sponsored by NOVARTIS